29/10/2026
We’re glad to share a talk from the BioGENext conference.
Oleksandr Hubar, Head of YP Biotech (the biotechnology products development lab) of YURiA-PHARM, presented our progress on a cap-less mRNA platform — a fully modular mRNA therapeutics design with in situ amplification potential.
What it’s about, briefly
Every mRNA drug on the market today starts with a “cap” — a chemical structure on the 5' end that keeps the molecule stable and tells the ribosome where to begin translation. It works, but it comes at a price: capping reagents and modified nucleotides account for roughly 80% of the cost of goods, lead times for key raw materials can stretch to a year, and the linear cap-dependent format puts a ceiling on how finely expression can be tuned.
Our approach removes the cap entirely and replaces it with two engineered RNA elements:
- a lariat-forming ribozyme (LCR), borrowed from a natural capping system found in mobile introns of amoebozoan rRNA genes, which stabilises the 5' end;
- an optimised IRES, which recruits the ribosome and starts translation without a cap.
Optimised LCRs reach about one-fifth of cap-dependent translation levels — and their activity proves highly context- and linker-dependent, which is exactly what we’re now mapping systematically.
For IRES optimisation we built a microfluidic DropSynth2-based screening system, with our own experiment-control software released openly: https://github.com/YP-Biotech/admet
An MPRA screen of 3'UTR libraries in CHO DG44 identified 7688 unique features, of which 89 showed more than 10-fold enrichment over baseline. Importantly, all selected elements remain active in N1-methylpseudouridine-modified RNA — so they are compatible with standard therapeutic mRNA chemistry.
Next: in vivo validation of optimal LCR-IRES constructs against CleanCap benchmarks, and integrated platform testing.
Watch the full talk: https://youtu.be/JwE6azT7FCk
Oleksandr Hubar | Head of biotechnology products development lab, S...